ClinicalTrials.gg
CompletedNCT06941077Updated Jun 11, 2025

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

A Phase 1 interventional study of INCB057643 in Healthy Volunteers, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • INCB057643
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Aged 18 to 55 years, inclusive, at the time of signing the ICF.
  • within the range of 18.0 to 30.0 kg/m2 inclusive. Note: Up to 25% of the participants in each cohort may be enrolled with a BMI > 30 to ≤ 32.0 kg/m2.
  • No findings on screening evaluations (clinical, laboratory, and ).
  • Ability to swallow and retain oral medication.

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
  • High blood pressure (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening, confirmed by repeat testing).
  • History or presence of an abnormal before screening and check-in that, in the investigator's opinion, is , such as a interval > 450 milliseconds, QRS interval > 120 milliseconds, or PR interval > 220 milliseconds.
  • History or presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
  • Hepatic transaminases ( and AST), ALP, or total > 1.25 × the laboratory-defined at screening and check-in, confirmed by repeat testing (except participants with Gilbert disease, for which total bilirubin must be ≤ 2.0 × ULN).
  • Any major surgery within 4 weeks of screening.
  • Current or recent (within 3 months of screening) clinically significant GI disease or surgery (including cholecystectomy and excluding appendectomy) that could affect the absorption of study drug.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
  • Positive test for , , or . Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
  • History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = 8 ounces of beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125-mL glass of wine, depending on type).
  • Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another medication or current enrollment in another investigational drug or investigational product study.
  • History of tobacco or nicotine-containing product use within 1 month of screening.
  • Use of prescription drugs (including hormonal ) within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional and standard-dose acetaminophen and ibuprofen and standard-dose vitamins are permitted. Megadose vitamins or supplements are not permissible.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1: Dose Treatment A

    INCB057643 will be administered at protocol defined dose.

    Drug: INCB057643

  • Experimental
    Cohort 2: Dose Treatment B

    INCB057643 will be administered at protocol defined dose.

    Drug: INCB057643

  • Experimental
    Cohort 3: Dose Treatment C

    INCB057643 will be administered at protocol defined dose.

    Drug: INCB057643

  • Experimental
    Cohort 4: Dose Treatment D

    INCB057643 will be administered at protocol defined dose.

    Drug: INCB057643

  • Experimental
    Cohort 4: Dose Treatment E

    INCB057643 will be administered at protocol defined dose.

    Drug: INCB057643

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter (PK): Cmax of INCB057643

    Defined as maximum observed plasma concentration of INCB057643.

    Time frame: Up to Day 10

  2. Pharmacokinetics Parameter: AUC(0-last) of INCB057643

    Defined as area under the single-dose serum concentration-time curve from time = 0 to the last measurable concentration at time of INCB057643.

    Time frame: Up to Day 10

  3. Pharmacokinetics Parameter: AUC 0-∞ of INCB057643

    Defined as the area under the single-dose serum concentration-time curve extrapolated to time of infinity of INCB057643.

    Time frame: Up to Day 10

Secondary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to Day 26

  2. Pharmacokinetics Parameter: Tmax of INCB057643

    Defined as the time to reach the maximum plasma concentration of INCB057643.

    Time frame: Up to Day 10

  3. Pharmacokinetics Parameter: t1/2 of INCB057643

    Defined as the apparent terminal phase disposition half-life of INCB057643.

    Time frame: Up to Day 10

  4. Pharmacokinetics Parameter: CL/F INCB057643

    Defined as the apparent oral dose clearance of INCB057643.

    Time frame: Up to Day 10

  5. Pharmacokinetics Parameter: V2/F of INCB057643

    Defined as the apparent oral dose volume of distribution of INCB057643.

    Time frame: Up to Day 10

  6. Pharmacokinetics Parameter: λz of INCB057643

    Defined as apparent terminal-phase disposition rate constant of INCB057643.

    Time frame: Up to Day 10

  7. Pharmacokinetics Parameter: %AUCexp of INCB057643

    Defined as percentage of AUC0-∞ due to extrapolation from the time of last quantifiable concentration to infinity of INCB057643.

    Time frame: Up to Day 10

07

Study locations

1 site
  • Celerion, Inc
    Tempe, Arizona 85283, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jun 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 23, 2025
StartActual
May 12, 2025
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06941077
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
May 12, 2025
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Jun 11, 2025

Study contacts

Incyte Study Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INCB057643

Start the discussion